Insulet (NASDAQ:PODD) Sets New 52-Week High on Analyst Upgrade

Key Points

• Insulet Corporation's stock reached a new 52-week high at $350.00 after Oppenheimer raised its price target from $324.00 to $365.00, maintaining an outperform rating on the stock.
• The company's quarterly earnings report showed a significant beat with earnings per share of $1.17, surpassing the consensus estimate of $0.92, and revenue of $649.10 million, up 32.9% year-over-year.
• Insulet has received strong endorsements from analysts with a consensus rating of "Moderate Buy", and substantial investments from large investors, indicating growing interest in the company's prospects.

Insulet Corporation (NASDAQ:PODD - Get Free Report) hit a new 52-week high on Monday after Oppenheimer raised their price target on the stock from $324.00 to $365.00. Oppenheimer currently has an outperform rating on the stock. Insulet traded as high as $350.00 and last traded at $346.70, with a volume of 74986 shares trading hands. The stock had previously closed at $348.43.

PODD has been the topic of a number of other research reports. Citigroup reaffirmed a "buy" rating on shares of Insulet in a report on Tuesday, July 8th. Wolfe Research raised Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 target price on the stock in a report on Tuesday, May 13th. Truist Financial started coverage on Insulet in a report on Monday, June 16th. They issued a "buy" rating and a $365.00 target price on the stock. The Goldman Sachs Group started coverage on Insulet in a report on Friday, May 30th. They issued a "buy" rating and a $380.00 target price on the stock. Finally, Wells Fargo & Company upped their target price on Insulet from $330.00 to $350.00 and gave the company an "overweight" rating in a report on Friday, August 8th. Sixteen investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Insulet presently has a consensus rating of "Moderate Buy" and a consensus target price of $335.12.

Hedge Funds Weigh In On Insulet

Large investors have recently modified their holdings of the company. Larson Financial Group LLC raised its holdings in shares of Insulet by 426.3% in the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier's stock worth $26,000 after purchasing an additional 81 shares during the period. Zions Bancorporation National Association UT acquired a new position in shares of Insulet in the 1st quarter worth approximately $26,000. SouthState Corp grew its position in shares of Insulet by 253.3% in the 1st quarter. SouthState Corp now owns 106 shares of the medical instruments supplier's stock worth $28,000 after acquiring an additional 76 shares in the last quarter. Kozak & Associates Inc. acquired a new position in shares of Insulet in the 2nd quarter worth approximately $32,000. Finally, Golden State Wealth Management LLC grew its position in shares of Insulet by 202.9% in the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier's stock worth $32,000 after acquiring an additional 69 shares in the last quarter.

Insulet Trading Down 0.4%

The company has a market cap of $24.43 billion, a price-to-earnings ratio of 105.59, a price-to-earnings-growth ratio of 2.92 and a beta of 1.36. The firm has a 50-day moving average price of $307.55 and a 200 day moving average price of $289.87. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.25. The business had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business's revenue was up 32.9% on a year-over-year basis. During the same quarter last year, the business posted $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, sell-side analysts forecast that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.